

CYP2C19 Poor Metabolizer Status and High System Inflammation Response Index are Independent Risk Factors for Premature Myocardial Infarction: A Hospital-Based Retrospective Study

Wendao Han, Nating Xiong, Renkai Zhong, Zhongyi Pan

Department of Blood Transfusion, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, People's Republic of China

Correspondence: Wendao Han, Department of Blood Transfusion, Meizhou People's Hospital, Meizhou, People's Republic of China, Email 443567914@qq.com

Objective: Atherosclerosis (AS) is a sustained chronic vascular inflammatory response caused by lipid metabolism disorders and immune response disorders and is the main cause of premature (men ≤ 55 years old, women ≤ 65 years old) myocardial infarction (PMI). Cytochrome P450 2C19 (CYP2C19) (related to vascular function and lipid metabolism) and peripheral immune cell levels and plays an important role in the course of AS. The association CYP2C19 polymorphisms, comprehensive immunoinflammatory indices with PMI susceptibility is unclear.

Methods: This study included 485 PMI patients, and 639 age-matched non-PMI individuals as controls, from January 2019 to March 2024. The relationship between CYP2C19 polymorphisms, peripheral immunoinflammatory indices (pan-immune inflammation value (PIV), systemic immune inflammation index (SII), and system inflammation response index (SIRI)) and PMI risk were analyzed.

Results: The inflammatory indices levels in PMI patients were higher than those in controls (all $p < 0.05$). The frequencies of the CYP2C19 *1/*2 and *2/*2 genotypes were higher, while the frequency of the *1/*1 genotype was lower in the PMI patients than those in controls. The cut-off values of TC, TG, LDL-C, PIV, SII, and SIRI were 5.065, 1.305, 2.805, 410.485, 869.645, and 1.495 for distinguishing PMI, respectively. Logistic regression analysis showed that male (odds ratio (OR): 1.607, 95% confidence interval (CI): 1.134–2.277, $p = 0.008$), history of smoking (OR: 7.108, 95% CI: 4.351–11.614, $p < 0.001$), diabetes mellitus (OR: 4.906, 95% CI: 3.333–7.223, $p < 0.001$), CYP2C19 poor metabolizer (PM) (*2/*2, *2/*3, and *3/*3) (OR: 2.147, 95% CI: 1.279–3.603, $p = 0.004$), and high TG (≥ 1.305 vs < 1.305 , OR: 2.598, 95% CI: 1.864–3.623, $p < 0.001$) and SIRI level (≥ 1.495 vs < 1.495 , OR: 2.495, 95% CI: 1.432–4.349, $p = 0.001$) were independent risk factors for PMI.

Conclusion: CYP2C19 PM phenotype, high SIRI level (≥ 1.495) and TG level (≥ 1.305), male, history of smoking, and diabetes mellitus were independently associated with PMI susceptibility.

Keywords: premature myocardial infarction, system inflammation response index, CYP2C19, polymorphism

Introduction

Cardiovascular disease (CVD) is a disease of the human cardiovascular system.^{1,2} CVD is the leading cause of death globally and a major contributor to the world's disease burden.³ Coronary artery disease (CAD) is a heart disease caused by coronary arteriosclerosis causing coronary artery stenosis, spasm and even occlusion, resulting in ischemia and hypoxia.^{4,5} Acute myocardial infarction (AMI) is the most serious type of CAD, which refers to a series of physiological and pathological changes occurring on the basis of coronary arteriosclerosis and stenosis, resulting in myocardial ischemia and hypoxia, which in turn induces myocardial necrosis.⁶

CVD generally occurs most frequently in the elderly, but with the increase in social pressure and the influence of bad living habits, the incidence of CVD in young individuals has gradually increased.^{7,8} In recent years, with the increasing incidence of AMI in young people, premature myocardial infarction (PMI) has received increasing attention.⁹ PMI refers to the occurrence of AMI when men ≤ 55 years old and women ≤ 65 years old.^{10–12} According to the results of the atherosclerosis risk in communities (ARIC) cohort study in the United States, the proportion of hospitalization for AMI in young patients has increased significantly from 1995 to 2014, and the 1-year all-cause mortality is close to 10%.¹³ PMI not only leads to a decrease in the young labor force but also brings no small burden to the social economy. Therefore, it is of great significance to study the risk factors of PMI for the prevention of PMI.

Atherosclerosis (AS) is the main pathological basis of coronary artery disease (CAD) and other arterial vascular diseases. It is characterized by the accumulation of lipids, the formation of diseased plaques, thickening of intima and narrowing of arterial spaces, which lead to ischemia or necrosis of tissues and organs supplied by arteries.^{14,15} AS is a sustained chronic vascular inflammatory response caused by multiple factors, mainly involving lipid metabolism disorders and immune response disorders.¹⁶ Innate and adaptive immunity involving neutrophils, lymphocytes, monocytes, and macrophages plays an important role in the occurrence and progression of AS.^{17–20} Neutrophils can promote monocyte recruitment by activating macrophages, play a cytotoxic role, and accelerate the progression of AS. Lymphocytes regulate inflammation and have anti-AS effects.²¹ Platelets interact with vascular endothelial cells and white blood cells to participate in the process of AS.²² In recent years, some comprehensive inflammatory indices calculated from peripheral blood cells have attracted wide attention, such as pan-immune inflammation value (PIV), systemic immune inflammation index (SII), and system inflammation response index (SIRI). Several studies have suggested that PIV,^{23,24} SII,^{25,26} and SIRI²⁷ were potential predictors of short- and long-term outcomes in patients with AMI. However, the relationship between these inflammatory indices and PMI has not been studied.

In addition, the pathophysiological processes of cardiovascular and cerebrovascular diseases may also be affected by cytochrome P450 (CYP450) enzymes.^{28,29} Specifically speaking, the metabolites of arachidonic acid (AA) and endothelial hyperpolarized factor (EDHF) catalyzed by CYP450 are the most important causes of vascular endothelial relaxation.^{30,31} Moreover, reactive oxygen species (ROS) are produced in coronary endothelial cells during the reaction catalyzed by CYP450, which can inhibit the vascular relaxation mediated by nitric oxide (NO).³² CYP450 2C19 (CYP2C19) is one of the important members of the CYP450 family.³³ The rs4244285 (681G>A, *CYP2C19*2*) and rs4986893 (636G>A, *CYP2C19*3*) are the most common single-nucleotide polymorphisms (SNPs) of *CYP2C19* gene. Based on the two SNPs, *CYP2C19* can be divided into six genotypes (*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3) and three phenotypes (extensive metabolizer (EM) (*CYP2C19*1*1*), intermediate metabolizer (IM) (*CYP2C19*1*2*, and *1/*3), and poor metabolizer (PM) (*CYP2C19*2*2*, *2/*3, and *3/*3)).³⁴ It has been found that poor CYP2C19 metabolizers were more likely to have recurrent myocardial infarction.³⁵

At present, there is little research on the risk factors for PMI. The purpose of this study was to investigate the association *CYP2C19* polymorphisms, PIV, SII, and SIRI indices with PMI susceptibility. This study may provide reference for improving the understanding of PMI, strengthening the control of controllable risk factors, and providing early prevention, diagnosis, and treatment of diseases.

Materials and Methods

Participants

This study retrospectively analyzed 485 PMI patients who were admitted to Meizhou People's Hospital from January 2019 to March 2024, and 639 age-matched non-AMI individuals as controls who underwent physical examination in Meizhou People's Hospital during the same period. The diagnostic criteria for AMI: the European Society of Cardiology (ESC) published the fourth edition of the Global Universal Diagnostic Criteria for myocardial infarction in 2018.³⁶ The diagnostic criteria for AMI were increased and/or decreased markers of acute myocardial injury, at least once above the 99th percentile of the upper limit of normal, and have at least one of the following clinical conditions: (1) symptoms of acute myocardial ischemia; (2) new ischemic electrocardiogram changes; (3) new pathological Q-wave; (4)

imaging evidence of newly viable myocardial loss or abnormal ventricular wall segmental motion; and (5) coronary angiography or intracavitary imaging confirmed the presence of coronary thrombosis.

Inclusion criteria of patients: (1) patients diagnosed with AMI; (2) patients who performed *CYP2C19* gene polymorphisms, serum lipid, and blood routine testing; (3) male patients aged ≤ 55 years old and female patients aged ≤ 65 years old; (4) the clinical information of the patients were complete. The inclusion criteria of the controls as follows: (1) non-AMI participants who had been performed *CYP2C19* gene polymorphisms, serum lipid, and blood routine testing; (2) male individuals with ≤ 55 years old and female individuals with ≤ 65 years old; (3) with complete information. Exclusion criteria for patients are as follows: (1) congenital heart disease, cardiomyopathy, or congestive heart failure; (2) with severe organ dysfunction; (3) with serious diseases, such as malignant tumors, severe infections, and so on. This study was supported by the Ethics Committee of the Meizhou People's Hospital.

Data Collection and *CYP2C19* Genotyping

Clinical data collected include gender, body mass index (BMI), ABO blood types, history of smoking, history of alcohol consumption, hypertension, and diabetes mellitus. According to Chinese standards, BMI was divided into three grades: < 18.5 kg/m², 18.5 – 23.9 kg/m², and ≥ 24.0 kg/m².^{37,38} Hypertension was defined as a mean systolic blood pressure > 140 mmHg and/or a mean diastolic blood pressure > 90 mmHg.³⁹ Diabetes mellitus was defined as blood glucose ≥ 11.1 mol/L at any time or fasting blood glucose ≥ 7.0 mol/L, or 2-hour postprandial plasma glucose level ≥ 11.1 mol/L.⁴⁰

Serum lipid levels and blood routine test data were collected before treatment. The patient's venous blood was collected, the serum lipid levels of the samples were evaluated by an Olympus AU5400 system (Olympus Corporation, Tokyo, Japan), and blood cell analysis was tested by Sysmex XE-2100 hematology analyzer (Sysmex Corporation, Japan) according to standard operating procedures (SOP). Genomic DNA was extracted from venous blood collected from EDTA anticoagulant collection vessels using a blood DNA isolation kit (Qiagen GmbH, Germany). *CYP2C19* genotyping was performed as previously described.^{41,42}

Statistical Analysis

The inflammation indices PIV, SII, and SIRI were calculated according to the following formula: (1) PIV = monocyte \times neutrophil \times platelet/lymphocyte; (2) SII = platelet \times neutrophil/lymphocyte; (3) SIRI = monocyte \times neutrophil/lymphocyte.

All statistical analyses were performed using SPSS statistical software (version 26.0, IBM Inc., USA). Continuous variables were compared using either Student's *t*-test, the Mann–Whitney *U*-test or analysis of variance (ANOVA). Genotype composition ratios and allele frequencies between groups were analyzed using *Chi*-square test or Fisher's exact test. Hardy-Weinberg equilibrium in the patients and controls was evaluated by *Chi*-square test. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff values of TC, TG, LDL-C, PIV, SII, and SIRI to distinguish PMI. Logistic regression analysis was applied to examine the association *CYP2C19* phenotypes, PIV, SII, and SIRI with PMI. $p < 0.05$ was considered to represent statistical significance.

Results

Characteristics of Subjects

Of the 1124 subjects, 590 (52.5%) were men and 534 (47.5%) were women, and the age was 53.0 (48.0, 57.0) years old. There were 214 (19.0%) cases had a history of smoking, 38 (3.4%) cases had a history of alcohol consumption, 548 (48.8%) cases had hypertension, and 248 (22.1%) cases had diabetes mellitus. There were 597 (53.1%) overweight individuals and 478 (42.5%) individuals with blood type O (Table 1).

There were significant differences in the distributions of gender and BMI between PMI patients group and controls (all $p < 0.05$). The proportion of history of smoking (34.8% vs 7.0%, $p < 0.001$) and diabetes mellitus (35.9% vs 11.6%, $p < 0.001$) in PMI patients was higher than those in controls, respectively. The serum lipid levels and inflammatory indices levels in PMI patients were significantly higher than those in controls (all $p < 0.05$). There was no statistically significant difference in the distribution of ABO blood types ($p = 0.187$) and proportion of history of alcohol consumption ($p = 0.068$), and hypertension ($p = 0.674$) between the two groups (Table 1).

Table 1 Comparison of Clinical Features Among PMI Patients and Controls

Variables	Total (n=1124)	Controls (n=639)	PMI Patients (n=485)	p values
Gender				
Male, n(%)	590(52.5%)	249(39.0%)	341(70.3%)	<0.001
Female, n(%)	534(47.5%)	390(61.0%)	144(29.7%)	
Age, years, median (P25, P75)	53.0 (48.0, 57.0)	53.0 (48.0, 58.0)	53.0 (47.0, 55.0)	0.052
BMI (kg/m ²)				
<18.5, n(%)	35(3.1%)	31(4.9%)	4(0.8%)	<0.001
18.5–23.9, n(%)	492(43.8%)	301(47.1%)	191(39.4%)	
≥24.0, n(%)	597(53.1%)	307(48.0%)	290(59.8%)	
ABO blood types				
A type, n(%)	342(30.4%)	187(29.3%)	155(32.0%)	0.187
B type, n(%)	245(21.8%)	146(22.8%)	99(20.4%)	
AB type, n(%)	59(5.2%)	27(4.2%)	32(6.6%)	
O type, n(%)	478(42.5%)	279(43.7%)	199(41.0%)	
History of smoking				
No, n(%)	910(81.0%)	594(93.0%)	316(65.2%)	<0.001
Yes, n(%)	214(19.0%)	45(7.0%)	169(34.8%)	
History of alcohol consumption				
No, n(%)	1086(96.6%)	623(97.5%)	463(95.5%)	0.068
Yes, n(%)	38(3.4%)	16(2.5%)	22(4.5%)	
Hypertension				
No, n(%)	576(51.2%)	331(51.8%)	245(50.5%)	0.674
Yes, n(%)	548(48.8%)	308(48.2%)	240(49.5%)	
Diabetes mellitus				
No, n(%)	876(77.9%)	565(88.4%)	311(64.1%)	<0.001
Yes, n(%)	248(22.1%)	74(11.6%)	174(35.9%)	
Serum lipid levels				
TC, mmol/L, median (P25, P75)	4.98 (4.25, 5.80)	4.84 (4.16, 5.62)	5.18 (4.38, 6.03)	<0.001
TG, mmol/L, median (P25, P75)	1.50 (1.08, 2.21)	1.30 (0.96, 1.93)	1.77 (1.29, 2.49)	<0.001
LDL-C, mmol/L, median (P25, P75)	2.83 (2.30, 3.45)	2.69 (2.18, 3.30)	2.97 (2.46, 3.68)	<0.001
Inflammatory indices levels				
PIV, median (P25, P75)	508.97 (249.94, 1035.92)	358.54 (178.08, 830.63)	711.70 (385.28, 1412.92)	<0.001
SII, median (P25, P75)	889.91 (532.20, 1600.66)	749.37 (447.72, 1391.80)	1122.78 (664.36, 1816.00)	<0.001
SIRI, median (P25, P75)	2.24 (1.05, 4.66)	1.54 (0.77, 3.62)	3.13 (1.67, 5.83)	<0.001

Abbreviations: PMI, premature myocardial infarction; BMI, body mass index; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; PIV, pan-immune-inflammation-value; SII, systemic immune-inflammation index; SIRI, systemic inflammatory response index; p25, 25th percentile; p75, 75th percentile.

Distribution Frequencies of the CYP2C19 Genotypes and Alleles in PMI Patients and Controls

There were 503 (44.8%), 404 (35.9%), 81 (7.2%), 97 (8.6%), 34 (3.0%), and 5 (0.4%) individuals carried *CYP2C19* *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotype, respectively. There were 503 (44.8%), 485 (43.1%), and 136 (12.1%) individuals with *CYP2C19* EM, IM, and PM phenotype, respectively. The results of Hardy–Weinberg equilibrium test showed that the *CYP2C19* genotypes in patients ($\chi^2=0.443$, $p=0.979$) and controls ($\chi^2=2.998$, $p=0.558$) conformed to the Hardy–Weinberg equilibrium, respectively. The frequencies of the *CYP2C19* *1/*2 genotype (39.4% vs 33.3%, $p=0.038$) and *CYP2C19* *2/*2 (10.7% vs 7.0%, $p=0.032$) genotype were higher, while the frequency of the *CYP2C19* *1/*1 (39.6% vs 48.7%, $p=0.002$) genotype was lower in the PMI patients than those in controls. The patients had higher frequency of the *2 allele (32.3% vs 25.0%, $p<0.001$) and lower frequency of *1 allele (62.5% vs 69.2%, $p=0.001$) than controls (Table 2).

Table 2 Distribution Frequencies of CYP2C19 Genotypes and Alleles in PMI Patients and Controls

CYP2C19 Phenotypes	CYP2C19 Genotypes/Alleles	Total (n=1124)	Controls (n=639)	PMI Patients (n=485)	χ^2	p values
Extensive metabolizer	*1/*1	503(44.8%)	311(48.7%)	192(39.6%)	9.199	0.002
	*1/*2	404(35.9%)	213(33.3%)	191(39.4%)		
Intermediate metabolizer	*1/*3	81(7.2%)	50(7.8%)	31(6.4%)	0.847	0.415
	*2/*2	97(8.6%)	45(7.0%)	52(10.7%)	4.734	0.032
Poor metabolizer	*2/*3	34(3.0%)	16(2.5%)	18(3.7%)	1.370	0.292
	*3/*3	5(0.4%)	4(0.6%)	1(0.2%)	1.097	0.397
	Alleles					
	*1	1491(66.3%)	885(69.2%)	606(62.5%)	11.332	0.001
	*2	632(28.1%)	319(25.0%)	313(32.3%)	14.569	<0.001
	*3	125(5.6%)	74(5.8%)	51(5.3%)	0.298	0.642
	HWE (χ^2 , P)	$\chi^2=2.197$, p=0.700	$\chi^2=2.998$, p=0.558	$\chi^2=0.443$, p=0.979		

Notes: *1, wild type; *2, 681 G>A; *3, 636 G>A.

Abbreviations: CYP2C19, cytochrome P450 2C19; PMI, premature myocardial infarction; HWE, Hardy Weinberg Equilibrium.

Clinical Characteristics of Subjects Stratified by CYP2C19 Phenotypes

Clinical characteristics and serum lipid-lipoprotein levels were compared among all subjects carried different *CYP2C19* phenotypes. The proportion of male individuals in *CYP2C19* IM group was higher than that in *CYP2C19* EM and PM groups (58.8% vs 46.9% and 50.7%, $p=0.001$). The individuals with *CYP2C19* EM phenotype had higher PIV level (537.03 (263.65, 1121.43) vs 492.84 (250.09, 947.85) and 424.15 (182.70, 892.58), $p=0.046$), and SII level (949.89 (592.32, 1799.15) vs 868.00 (522.87, 1524.29) and 690.00 (420.02, 1256.71), $p<0.001$) than those with *CYP2C19* IM phenotype and PM phenotype, respectively (Table 3).

Logistic Regression Analysis of Risk Factors for PMI

When PMI was taken as the endpoint of serum lipid levels, the critical value of TC was 5.065 (sensitivity 53.8%, specificity 58.3%, area under the ROC curve (AUC): 0.577), the LDL-C cutoff value was 2.805 (sensitivity 60.4%, specificity 54.6%, AUC: 0.588), the TG cutoff value was 1.305 (sensitivity 74.0%, specificity 50.5%, AUC: 0.651) (Figure 1A). When PMI was considered as the endpoint of inflammatory indices levels, the SII cutoff value was 869.645

Table 3 Clinical Characteristics of Subjects Stratified by CYP2C19 Phenotypes

Variables	Extensive Metabolizer (n=503)	Intermediate Metabolizer (n=485)	Poor Metabolizer (n=136)	p values
Gender				
Male, n(%)	236(46.9%)	285(58.8%)	69(50.7%)	0.001 ($\chi^2=14.082$)
Female, n(%)	267(53.1%)	200(41.2%)	67(49.3%)	
BMI (kg/m ²)				
<18.5, n(%)	17(3.4%)	14(2.9%)	4(2.9%)	0.689 ($\chi^2=2.252$)
18.5–23.9, n(%)	224(44.5%)	216(44.5%)	52(38.2%)	
≥24.0, n(%)	262(52.1%)	255(52.6%)	80(58.8%)	
ABO blood types				
A type, n(%)	150(29.8%)	152(31.3%)	40(29.4%)	0.943 ($\chi^2=1.649$)
B type, n(%)	112(22.3%)	107(22.1%)	26(19.1%)	
AB type, n(%)	25(5.0%)	25(5.2%)	9(6.6%)	
O type, n(%)	216(42.9%)	201(41.4%)	61(44.9%)	
History of smoking				
No, n(%)	414(82.3%)	387(79.8%)	109(80.1%)	0.580 ($\chi^2=1.078$)
Yes, n(%)	89(17.7%)	98(20.2%)	27(19.9%)	

(Continued)

Table 3 (Continued).

Variables	Extensive Metabolizer (n=503)	Intermediate Metabolizer (n=485)	Poor Metabolizer (n=136)	p values
History of alcohol consumption				
No, n(%)	485(96.4%)	472(97.3%)	129(94.9%)	0.321
Yes, n(%)	18(3.6%)	13(2.7%)	7(5.1%)	($\chi^2=2.087$)
Hypertension				
No, n(%)	260(51.7%)	244(50.3%)	72(52.9%)	0.837
Yes, n(%)	243(48.3%)	241(49.7%)	64(47.1%)	($\chi^2=0.366$)
Diabetes mellitus				
No, n(%)	395(78.5%)	379(78.1%)	102(75.0%)	0.654
Yes, n(%)	108(21.5%)	106(21.9%)	34(25.0%)	($\chi^2=0.797$)
Serum lipid levels				
TC, mmol/L, median (P25, P75)	4.94 (4.23, 5.81)	5.04 (4.28, 5.79)	4.93 (4.27, 5.65)	0.620
TG, mmol/L, median (P25, P75)	1.46 (1.06, 2.21)	1.52 (1.10, 2.18)	1.54 (1.05, 2.42)	0.573
LDL-C, mmol/L, median (P25, P75)	2.79 (2.25, 3.46)	2.88 (2.34, 3.49)	2.81 (2.25, 3.29)	0.457
Inflammatory indices levels				
PIV, median (P25, P75)	37.03 (263.65, 1121.43)	492.84 (250.09, 947.85)	424.15 (182.70, 892.58)	0.046
SII, median (P25, P75)	949.89 (592.32, 1799.15)	868.00 (522.87, 1524.29)	690.00 (420.02, 1256.71)	<0.001
SIRI, median (P25, P75)	2.32 (1.12, 4.93)	2.18 (1.05, 4.77)	2.00 (0.72, 4.02)	0.087

Abbreviations: CYP2C19, cytochrome P450 2C19; BMI, body mass index; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; PIV, pan-immune-inflammation-value; SII, systemic immune-inflammatory index; SIRI, systemic inflammatory response index; p25, 25th percentile; p75, 75th percentile.

(sensitivity 62.1%, specificity 57.7%, AUC: 0.623), the SIRI cutoff value was 1.495 (sensitivity 79.7%, specificity 49.4%, AUC: 0.676), and the PIV cutoff value was 410.485 (sensitivity 73.0%, specificity 56.2%, AUC: 0.677) (Figure 1B).

The results of univariate analysis showed that male (male vs female, odds ratio (OR): 3.709, 95% confidence interval (CI): 2.884–4.769, $p < 0.001$), overweight (BMI ≥ 24.0 kg/m² vs BMI 18.5–23.9 kg/m², OR: 1.489, 95% CI: 1.169–1.897, $p = 0.001$), history of smoking (yes vs no, OR: 7.059, 95% CI: 4.945–10.078, $p < 0.001$), diabetes mellitus (yes vs no, OR: 4.272, 95% CI: 3.148–5.796, $p < 0.001$), CYP2C19 IM phenotype (IM phenotype vs EM phenotype, OR: 1.367, 95% CI: 1.061–1.762, $p = 0.016$) and PM phenotype (PM phenotype vs EM phenotype, OR: 1.769, 95% CI: 1.208–2.591, $p = 0.003$), and high serum lipid levels, and inflammatory indices levels were




Figure 1 The ROC curve analysis of TC, TG, LDL-C, PIV, SII, and SIRI to distinguish PMI. The ROC curve of TC, TG, and LDL-C (A); the ROC curve of PIV, SII, and SIRI (B). **Abbreviations:** TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; PIV, pan-immune-inflammation-value; SII, systemic immune-inflammatory index; SIRI, systemic inflammatory response index; PMI, premature myocardial infarction.

Table 4 Logistic Regression Analysis of Risk Factors for PMI

Variables	Univariate OR (95% CI)	p values	Multivariate OR (95% CI)	p values
Gender (Male vs Female)	3.709 (2.884–4.769)	<0.001	1.607 (1.134–2.277)	0.008
BMI (kg/m ²)				
18.5–23.9	1.000 (reference)	–	1.000 (reference)	–
<18.5	0.203 (0.071–0.585)	0.003	0.412 (0.121–1.399)	0.155
≥24.0	1.489 (1.169–1.897)	0.001	1.300 (0.946–1.787)	0.106
ABO blood types (non-O type vs O type)	1.114 (0.877–1.415)	0.377	1.031 (0.756–1.407)	0.846
History of smoking (Yes vs No)	7.059 (4.945–10.078)	<0.001	7.108 (4.351–11.614)	<0.001
History of alcoholism (Yes vs No)	1.850 (0.961–3.562)	0.066	0.254 (0.099–0.654)	0.004
Hypertension (Yes vs No)	1.053 (0.831–1.333)	0.670	0.730 (0.531–1.003)	0.052
Diabetes mellitus (Yes vs No)	4.272 (3.148–5.796)	<0.001	4.906 (3.333–7.223)	<0.001
CYP2C19 phenotypes				
Extensive metabolizer	1.000 (reference)	–	1.000 (reference)	–
Intermediate metabolizer	1.367 (1.061–1.762)	0.016	1.298 (0.935–1.800)	0.119
Poor metabolizer	1.769 (1.208–2.591)	0.003	2.147 (1.279–3.603)	0.004
TC (≥5.065 vs <5.065)	1.624 (1.273–2.072)	<0.001	1.124 (0.725–1.742)	0.601
TG (≥1.305 vs <1.305)	2.900 (2.233–3.767)	<0.001	2.598 (1.864–3.623)	<0.001
LDL-C (≥2.805 vs <2.805)	1.839 (1.439–2.351)	<0.001	1.518 (0.980–2.353)	0.062
PIV (≥410.485 vs <410.485)	3.461 (2.674–4.480)	<0.001	1.679 (0.953–2.959)	0.073
SII (≥869.645 vs <869.645)	2.229 (1.744–2.849)	<0.001	1.036 (0.659–1.629)	0.878
SIRI (≥1.495 vs <1.495)	3.828 (2.910–5.035)	<0.001	2.495 (1.432–4.349)	0.001

Abbreviations: PMI, premature myocardial infarction; BMI, body mass index; CYP2C19, cytochrome P450 2C19; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; PIV, pan-immune-inflammation-value; SII, systemic immune-inflammatory index; SIRI, systemic inflammatory response.

significantly associated with PMI. Multivariate logistic regression analysis showed that male (male vs female, OR: 1.607, 95% CI: 1.134–2.277, $p=0.008$), history of smoking (yes vs no, OR: 7.108, 95% CI: 4.351–11.614, $p<0.001$), diabetes mellitus (yes vs no, OR: 4.906, 95% CI: 3.333–7.223, $p<0.001$), *CYP2C19* PM phenotype (PM phenotype vs EM phenotype, OR: 2.147, 95% CI: 1.279–3.603, $p=0.004$), and high TG level (≥ 1.305 vs <1.305 , OR: 2.598, 95% CI: 1.864–3.623, $p<0.001$) and SIRI level (≥ 1.495 vs <1.495 , OR: 2.495, 95% CI: 1.432–4.349, $p=0.001$) were independent risk factors for PMI (Table 4).

Discussion

AS is a multifactor-induced chronic inflammatory disease involving a complex set of circulating blood cells (such as blood plates and monocytes) and serum components (such as lipids and lipoproteins).^{43,44} AS is the common pathological basis of AMI, which is characterized by plaque formed by the coronary arteries loaded with lipids and a variety of immune cells.⁴⁵ Neutrophils are involved in different stages of AS, including AS formation, rupture of unstable plaques, and plaque erosion.¹⁸ The granular protein and active substances released by granulocytes induce the recruitment of monocytes to AS lesions, stimulate the activation of macrophages, and promote the formation of foam cells.^{18,19} T helper 17 (Th17) cells induce the production of pro-inflammatory cytokines, and secreted interleukin-17 (IL-17) can up-regulate the expression of E-selectin and intercellular adhesion molecules, thus promoting the generation of AS plaques.⁴⁶ IgM produced by B1 lymphocytes can block the production of inflammatory cytokines and the formation of foam cells induced by oxidized low-density lipoprotein (ox-LDL) and has anti-AS effect.²⁰ Monocyte-macrophages can absorb ox-LDL and release pro-inflammatory and pro-oxidative cytokines to further attract T lymphocytes and monocytes to the plaque site.⁴⁷ Platelets regulate the inflammatory response of vascular endothelial cells and smooth muscle cells and thus participate in the process of AS.²² The predictive value of inflammatory indices based on cell counts of neutrophils, lymphocytes, monocytes, and platelets in cardiovascular diseases has been widely concerned.

Several studies have suggested that PIV,^{23,24} SII,^{25,26,48–51} and SIRI,^{27,48,51} comprehensive indicators based on the above immune cell levels, were potential predictors of short- and long-term outcomes in patients with AMI. In

addition, PIV can be used as a marker of the severity of CAD.⁵² Several researches had found that PIV,⁵³ SII,^{54–58} and SIRI⁵³ can be used to predict the risk of major cardiovascular events (MACE) after coronary intervention in patients with CAD. However, the relationship between these inflammatory indices and PMI has not been studied. A large, prospective, population-based cohort study showed that elevated SIRI was associated with an increased incidence of myocardial infarction in subjects aged <60 years old.⁵⁹ The results of this study suggest that high SIRI levels (≥ 1.495) may be an independent risk factor for PMI.

Moreover, PMI is also associated with traditional cardiovascular risk factors such as smoking, diabetes mellitus, and lipid disorders.⁶⁰ Most studies have largely identified smoking as a risk factor for early onset of AMI.^{61–63} Nicotine and other chemicals in cigarette tar promote AS through various mechanisms, such as mediating the damage to endothelial cell nucleus and mitochondrial DNA, increasing the expression of inflammatory factors, and promoting thrombosis.⁶⁴ In addition, elevation in TG level was associated with high risk of PMI.⁶⁵ AMI in young patients was associated with dyslipidemia.⁶² Triglyceride-glucose index can be used for the prediction of premature CAD⁶⁶ and MACE in patients with premature CAD.⁶⁷ Some studies suggested that LDL-C abnormality is the main cause of dyslipidemia that causes early onset cardiovascular disease.^{68,69} However, this study did not find a significant association between LDL-C levels and PMI risk.

In this study, *CYP2C19* PM phenotype was an independent risk factor for PMI. To our knowledge, little is known about the relationship between *CYP2C19* polymorphism and PMI susceptibility. Xie et al found that *CYP2C19* *2/*2 genotype was an independent risk factor for multi-site AS.⁴¹ Several studies found that *CYP2C19* polymorphism was a risk factor for CAD.^{70–73} In addition, other studies have suggested that *CYP2C19* polymorphism was associated with the prognosis of CAD patients after percutaneous coronary intervention (PCI).^{74,75} In terms of mechanism, CYP450 may be involved in the development of atherosclerosis in several ways, such as EDHF produced from AA catalyzed by CYP450 is an important factor in vascular endothelial relaxation,^{30,31} the catalytic product of CYP450 modulates NO mediated vasodilation,³² and CYP450 regulates lipid deposition in blood vessels.²⁹ *CYP2C19* is an important member of the CYP450 family, *CYP2C19* poor metabolizer with only weak enzyme activity, and its metabolites are not enough to maintain the balance of the above processes, so poor metabolizers are more prone to AS. Therefore, routine testing of *CYP2C19* polymorphism is of great value for early detection of PMI high-risk groups.

To the best of our knowledge, this study is the first to report on *CYP2C19* gene polymorphisms, PIV, SII, and SIRI levels and PMI susceptibility. Importantly, individuals with a *CYP2C19* PM phenotype and high SIRI levels need to be alert to the risk of developing PMI. To sum up, SIRI and *CYP2C19* gene testing have the advantages of strong universality, convenient operation, and low cost-efficiency. We believe that SIRI and *CYP2C19* polymorphism can provide reference for the identification and management of PMI patients. This study was a single-center retrospective study with a small sample size, which may lead to selection bias. Therefore, multicenter, prospective studies are needed to further verify the predictive value of SIRI and *CYP2C19* gene polymorphisms for PMI.

Conclusion

In summary, *CYP2C19* PM phenotype, high SIRI level (≥ 1.495) and TG level (≥ 1.305), male, history of smoking, and diabetes mellitus were independently associated with PMI susceptibility. It means that male smokers who have diabetes mellitus, carried *CYP2C19* PM phenotype, and have high TG and SIRI levels need to be aware of the risk of developing PMI. It can provide reference for the identification and management of PMI patients.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval

All participants were informed on the study procedures and goals and the informed consent from all the participants. The study was performed under the guidance of the Declaration of Helsinki and approved by the Ethics Committee of Medicine, Meizhou People's Hospital.

Acknowledgments

The authors thank their colleagues, who were not listed in the authorship of the Department of Blood Transfusion, Meizhou People's Hospital, for their helpful comments on the manuscript.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by the Science and Technology Program of Meizhou (Grant No.: 2019B0202001).

Disclosure

The authors declare that they have no competing interests.

References

1. Valenzuela PL, Ruilope LM. Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation. *Eur Heart J.* 2023;44(21):1874–1889. doi:10.1093/eurheartj/ehad170
2. Chapman FA, Maguire JJ, Newby DE. Targeting the apelin system for the treatment of cardiovascular diseases. *Cardiovasc Res.* 2023;119(17):2683–2696. doi:10.1093/cvr/cvad171
3. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol.* 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010
4. Shaya GE, Leucker TM, Jones SR, Martin SS, Toth PP. Coronary heart disease risk: low-density lipoprotein and beyond. *Trends Cardiovasc Med.* 2022;32(4):181–194. doi:10.1016/j.tcm.2021.04.002
5. Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary atherosclerosis and clinical implications for chronic ischemic heart disease management—the plaque hypothesis: a narrative review. *JAMA Cardiol.* 2023;8(2):192–201. doi:10.1001/jamacardio.2022.3926
6. Tirdea C, Hostiuc S. Identification of risk genes associated with myocardial infarction-big data analysis and literature review. *Int J Mol Sci.* 2022;23(23):15008. doi:10.3390/ijms232315008
7. Wang X, Gao M, Zhou S, et al. Trend in young coronary artery disease in China from 2010 to 2014: a retrospective study of young patients ≤ 45. *BMC Cardiovasc Disord.* 2017;17(1):18. doi:10.1186/s12872-016-0458-1
8. Salomaa V. Worrying trends in the incidence of coronary artery disease events among young individuals. *Eur J Prev Cardiol.* 2020;27(11):1175–1177. doi:10.1177/2047487319896051
9. Kayikcioglu M, Ozkan HS. Premature myocardial infarction: a rising threat. *Balkan Med J.* 2022;39(2):83–95. doi:10.4274/balkanmedj.galenos.2022-2-19
10. Dugani SB, Ayala Melendez AP, Reka R. Risk factors associated with premature myocardial infarction: a systematic review protocol. *BMJ Open.* 2019;9(2):e023647. doi:10.1136/bmjopen-2018-023647
11. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation.* 2002;106(25):3143–3421. PMID: 12485966.
12. Medina-Urrutia AX, Martínez-Sánchez FD, Posadas-Romero C, et al. Metabolic control achievement in a population with premature coronary artery disease: results of the genetics of atherosclerotic disease study. *Ther Adv Endocrinol Metab.* 2020;11:2042018820943374. doi:10.1177/2042018820943374
13. Arora S, Stouffer GA, Kucharska-Newton AM, et al. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. *Circulation.* 2019;139(8):1047–1056. doi:10.1161/CIRCULATIONAHA.118.037137
14. Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. *Adv Exp Med Biol.* 2020;1177:1–36. doi:10.1007/978-981-15-2517-9_1
15. Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression: JACC state-of-the-art review. *J Am Coll Cardiol.* 2022;79(1):66–82. doi:10.1016/j.jacc.2021.10.035
16. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. *Circ Res.* 2019;124(2):315–327. doi:10.1161/CIRCRESAHA.118.313591
17. Björkegren JLM, Lusis AJ. Atherosclerosis: recent developments. *Cell.* 2022;185(10):1630–1645. doi:10.1016/j.cell.2022.04.004
18. Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. *Nat Rev Cardiol.* 2020;17(6):327–340. doi:10.1038/s41569-019-0326-7
19. An Z, Li J, Yu J, et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. *Cell Cycle.* 2019;18(21):2928–2938. doi:10.1080/15384101.2019.1662678
20. Srikakulapu P, Upadhye A, Rosenfeld SM, et al. Perivascular adipose tissue harbors atheroprotective IgM-producing B cells. *Front Physiol.* 2017;8:719. doi:10.3389/fphys.2017.00719
21. Rasmuson J, Kenne E, Wahlgren M, Soehnlein O, Lindbom L. Heparinoid seviparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins. *FASEB J.* 2019;33(9):10443–10452. doi:10.1096/fj.201900627R

22. Wang L, Tang C. Targeting platelet in atherosclerosis plaque formation: current knowledge and future perspectives. *Int J Mol Sci.* 2020;21(24):9760. doi:10.3390/ijms21249760
23. Murat B, Murat S. Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction. *Eur J Clin Invest.* 2023;53(1):e13872. doi:10.1111/eci.13872
24. Şen F, Kurtul A, Bekler Ö. Pan-immune-inflammation value is independently correlated to impaired coronary flow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. *Am J Cardiol.* 2024;211:153–159. doi:10.1016/j.amjcard.2023.10.088
25. Luo J, Qin X, Zhang X, et al. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry. *Cardiovasc Diabetol.* 2024;23(1):41. doi:10.1186/s12933-024-02129-x
26. Bağcı A, Aksoy F. Systemic immune-inflammation index predicts new-onset atrial fibrillation after ST elevation myocardial infarction. *Biomarker Med.* 2021;15(10):731–739. doi:10.2217/bmm-2020-0838
27. Ozilhan MO, Çakmak Karaaslan O, Acikgoz SK, Selcuk H, Selcuk MT, Maden O. Systemic inflammation response index is associated MACE in patients with NSTEMI. *Eur Rev Med Pharmacol Sci.* 2023;27(18):8588–8597. doi:10.26355/eurrev_202309_33783
28. Jamieson KL, Endo T, Darwesh AM, Samokhvalov V, Seubert JM. Cytochrome P450-derived eicosanoids and heart function. *Pharmacol Ther.* 2017;179:47–83. doi:10.1016/j.pharmthera.2017.05.005
29. Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis. *Asian Pac J Cancer Prev.* 2018;19(8):2057–2070. doi:10.22034/APJCP.2018.19.8.2057
30. Fisslthaler B, Fleming I, Busse R. EDHF: a cytochrome P450 metabolite in coronary arteries. *Semin Perinatol.* 2000;24(1):15–19. doi:10.1016/s0146-0005(00)80048-8
31. Chawengsub Y, Gauthier KM, Campbell WB. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. *Am J Physiol Heart Circ Physiol.* 2009;297(2):H495–507. doi:10.1152/ajpheart.00349.2009
32. Fleming I, Michaelis UR, Bredenkötter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. *Circ Res.* 2001;88(1):44–51. doi:10.1161/01.res.88.1.44
33. Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. *Pharmacogenomics.* 2020;21(12):889–897. doi:10.2217/pgs-2020-0046
34. Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. *Br J Clin Pharmacol.* 2022;88(7):3288–3296. doi:10.1111/bcp.15268
35. Magavern EF, Jacobs B, Warren H, et al. CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel. *JACC Adv.* 2023;2(7):100573. doi:10.1016/j.jacadv.2023.100573
36. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol.* 2018;72(18):2231–2264. doi:10.1016/j.jacc.2018.08.1038
37. He W, Li Q, Yang M, et al. Lower BMI cutoffs to define overweight and obesity in China. *Obesity.* 2015;23(3):684–691. doi:10.1002/oby.20995
38. Tang J, Zhu X, Chen Y, et al. Association of maternal pre-pregnancy low or increased body mass index with adverse pregnancy outcomes. *Sci Rep.* 2021;11(1):3831. doi:10.1038/s41598-021-82064-z
39. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. *Circulation.* 2018;137(22):2344–2356. doi:10.1161/CIRCULATIONAHA.117.032380
40. Benhalima K, Van Crombrugge P, Moyson C, et al. Risk factor screening for gestational diabetes mellitus based on the 2013 WHO criteria. *Eur J Endocrinol.* 2019;180(6):353–363. doi:10.1530/EJE-19-0117
41. Xie J, Pan T, Luo W, Zhang S, Fang Y, Xu Z. CYP2C19 *2/*2 genotype is a risk factor for multi-site arteriosclerosis: a hospital-based cohort study. *Int J Gen Med.* 2023;16:5139–5146. doi:10.2147/IJGM.S437251
42. Cai N, Li C, Gu X, et al. CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study. *BMC Cardiovasc Disord.* 2023;23(1):185. doi:10.1186/s12872-023-03207-w
43. Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. *Int J Mol Sci.* 2022;23(21):12906. doi:10.3390/ijms232112906
44. Nikiforov NG, Kirichenko TV, Kubekina MV, et al. Macrophages derived from LPS-stimulated monocytes from individuals with subclinical atherosclerosis were characterized by increased pro-inflammatory activity. *Cytokine.* 2023;172:156411. doi:10.1016/j.cyto.2023.156411
45. Gobbi G, Carubbi C, Tagliazucchi GM, Masselli E, Mirandola P, Pigazzani F. Sighting acute myocardial infarction through platelet gene expression. *Sci Rep.* 2019;9(1):19574. doi:10.1038/s41598-019-56047-0
46. Taleb S, Tedgui A. IL-17 in atherosclerosis: the good and the bad. *Cardiovasc Res.* 2018;114(1):7–9. doi:10.1093/cvr/cvx225
47. Ganjali S, Gotto AM Jr, Ruscica M, Atkin SL. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. *J Cell Physiol.* 2018;233(12):9237–9246. doi:10.1002/jcp.27028
48. Wei X, Zhang Z, Wei J, Luo C. Association of systemic immune inflammation index and system inflammation response index with clinical risk of acute myocardial infarction. *Front Cardiovasc Med.* 2023;10:1248655. doi:10.3389/fcvm.2023.1248655
49. Zhu Y, He H, Qiu H, Shen G, Wang Z, Li W. Prognostic value of systemic immune-inflammation index and NT-proBNP in patients with acute ST-elevation myocardial infarction. *Clin Interv Aging.* 2023;18:397–407. doi:10.2147/CIA.S397614
50. Orhan AL, Şaylık F, Çiçek V, Akbulut T, Selçuk M, Çınar T. Evaluating the systemic immune-inflammation index for in-hospital and long-term mortality in elderly non-ST-elevation myocardial infarction patients. *Aging Clin Exp Res.* 2022;34(7):1687–1695. doi:10.1007/s40520-022-02103-1
51. Marchi F, Pylypiv N, Parlanti A, Storti S, Gaggini M. Systemic immune-inflammation index and systemic inflammatory response index as predictors of mortality in ST-elevation myocardial infarction. *J Inflamm Res.* 2024;13(5):3437–3454. doi:10.2147/JIR.S421491
52. Cetinkaya Z, Kelesoglu S, Tuncay A, et al. The role of pan-immune-inflammation value in determining the severity of coronary artery disease in NSTEMI patients. *J Clin Med.* 2024;13(5):1295. doi:10.3390/jcm13051295
53. Liu Y, Liu J, Liu L, et al. Association of systemic inflammatory response index and pan-immune-inflammation-value with long-term adverse cardiovascular events in ST-segment elevation myocardial infarction patients after primary percutaneous coronary intervention. *J Inflamm Res.* 2023;16:3437–3454. doi:10.2147/JIR.S421491
54. Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. *Eur J Clin Invest.* 2020;50(5):e13230. doi:10.1111/eci.13230

55. Saylik F, Akbulut T. Systemic immune-inflammation index predicts major cardiovascular adverse events in patients with ST-segment elevated myocardial infarction. *Arq Bras Cardiol.* 2022;119(1):14–22. doi:10.36660/abc.20210412
56. Li X, Yu C, Liu X, et al. A prediction model based on systemic immune-inflammatory index combined with other predictors for major adverse cardiovascular events in acute myocardial infarction patients. *J Inflamm Res.* 2024;17:1211–1225. doi:10.2147/JIR.S443153
57. Huang J, Zhang Q, Wang R, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. *Med Sci Monit.* 2019;25:9690–9701. doi:10.12659/MSM.919802
58. Zhang C, Li M, Liu L, et al. Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies. *BMC Cardiovasc Disord.* 2024;24(1):189. doi:10.1186/s12872-024-03849-4
59. Jin Z, Wu Q, Chen S, et al. The associations of two novel inflammation indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: a ten-year follow-up study in 85,154 individuals. *J Inflamm Res.* 2021;14:131–140. doi:10.2147/JIR.S283835
60. Rallidis LS, Xenogiannis I, Brilakis ES, Bhatt DL. Causes, angiographic characteristics, and management of premature myocardial infarction: JACC state-of-the-art review. *J Am Coll Cardiol.* 2022;79(24):2431–2449. doi:10.1016/j.jacc.2022.04.015
61. Rallidis LS, Sakadakis EA, Tympas K, et al. The impact of smoking on long-term outcome of patients with premature (≤ 35 years) ST-segment elevation acute myocardial infarction. *Am Heart J.* 2015;169(3):356–362. doi:10.1016/j.ahj.2014.12.003
62. Liu Q, Shi RJ, Zhang YM, et al. Risk factors, clinical features, and outcomes of premature acute myocardial infarction. *Front Cardiovasc Med.* 2022;9:1012095. doi:10.3389/fcvm.2022.1012095
63. Wienbergen H, Boakye D, Günther K. Lifestyle and metabolic risk factors in patients with early-onset myocardial infarction: a case-control study. *Eur J Prev Cardiol.* 2022;29(16):2076–2087. doi:10.1093/eurjpc/zwac132
64. Ueda K, Sakai C, Ishida T, et al. Cigarette smoke induces mitochondrial DNA damage and activates cGAS-STING pathway: application to a biomarker for atherosclerosis. *Clin Sci.* 2023;137(2):163–180. doi:10.1042/CS20220525
65. Dugani SB, Hydoub YM, Ayala AP, et al. Risk factors for premature myocardial infarction: a systematic review and meta-analysis of 77 studies. *Mayo Clin Proc Innov Qual Outcomes.* 2021;5(4):783–794. doi:10.1016/j.mayocpiqo.2021.03.009
66. Wei A, Liu J, Wang L, Zheng S. Correlation of triglyceride-glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin, China. *BMJ Open.* 2022;12(9):e065780. doi:10.1136/bmjopen-2022-065780
67. Wu Z, Liu L, Wang W, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. *Cardiovasc Diabetol.* 2022;21(1):142. doi:10.1186/s12933-022-01576-8
68. Bødtker H, Gunnarsen S, Adelborg K, et al. Association between lipid fractions and age of first myocardial infarction. *Scand Cardiovasc J.* 2020;54(6):346–351. doi:10.1080/14017431.2020.1770850
69. Beheshti S, Madsen CM, Varbo A, Nordestgaard BG. How to identify familial premature myocardial infarction: comparing approaches to identify familial hypercholesterolemia. *J Clin Endocrinol Metab.* 2019;104(7):2657–2667. doi:10.1210/je.2018-02261
70. Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. *Clin Appl Thromb Hemost.* 2010;16(5):579–583. doi:10.1177/1076029610364522
71. Hokimoto S, Tabata N, Akasaka T, et al. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease. *J Cardiovasc Pharmacol.* 2015;65(2):148–152. doi:10.1097/FJC.0000000000000171
72. Shi Y, Yang Y, Feng M, et al. Differences in the proportion of CYP2C19 loss-of-function between cerebral infarction and coronary artery disease patients. *Int J Gen Med.* 2023;16:3473–3481. doi:10.2147/IJGM.S420108
73. Akasaka T, Hokimoto S, Sueta D, et al. Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. *Am J Physiol Heart Circ Physiol.* 2016;310(11):H1494–1500. doi:10.1152/ajpheart.00911.2015
74. Wang W, Shao C, Xu B, et al. CYP2C19 genotype has prognostic value in specific populations following coronary stenting. *Ann Transl Med.* 2021;9(13):1066. doi:10.21037/atm-20-7724
75. Luo Y, Zhao YT, Verdo A, Qi WG, Zhang DF, Hu B. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. *J Int Med Res.* 2011;39(5):2012–2019. doi:10.1177/147323001103900548

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>